Lipodystrophy - Pipeline Review, H2 2016

  • ID: 3846561
  • Drug Pipelines
  • 51 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Akcea Therapeutics Inc
  • Ambrx, Inc.
  • Amunix Operating Inc.
  • MORE
Lipodystrophy - Pipeline Review, H2 2016

Summary

‘Lipodystrophy - Pipeline Review, H2 2016’, provides an overview of the Lipodystrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lipodystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lipodystrophy and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lipodystrophy
- The report reviews pipeline therapeutics for Lipodystrophy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lipodystrophy therapeutics and enlists all their major and minor projects
- The report assesses Lipodystrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lipodystrophy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lipodystrophy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lipodystrophy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Akcea Therapeutics Inc
  • Ambrx, Inc.
  • Amunix Operating Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Lipodystrophy Overview

Therapeutics Development

Pipeline Products for Lipodystrophy - Overview

Lipodystrophy - Therapeutics under Development by Companies

Lipodystrophy - Pipeline Products Glance

Late Stage Products

Early Stage Products

Lipodystrophy - Products under Development by Companies

Lipodystrophy - Companies Involved in Therapeutics Development

Aegerion Pharmaceuticals, Inc.

Akcea Therapeutics Inc

Ambrx, Inc.

Amunix Operating Inc.

Bolder Biotechnology, Inc.

Lipodystrophy - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AMX-342 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARX-328 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBT-031 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

metreleptin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

volanesorsen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lipodystrophy - Product Development Milestones

Featured News & Press Releases

Jul 28, 2016: Akcea Therapeutics Receives Orphan Designation in Europe for Volanesorsen for the Treatment of Familial Partial Lipodystrophy

Jun 27, 2016: Akcea Announces Publication of Positive Volanesorsen Clinical Data Showing Reduced Triglycerides and Improved Insulin Sensitivity in Patients with High Triglycerides and Type 2 Diabetes

May 29, 2014: Zydus Explores Newer Treatment Options With its Breakthrough Drug, Lipaglyn

Feb 25, 2014: FDA approves Myalept to treat rare metabolic disease

Dec 12, 2013: FDA Advisory Committee votes on investigational medicine metreleptin

Jun 04, 2013: Bristol-Myers Squibb And AstraZeneca Receive FDA Priority Review Designation For Metreleptin

May 06, 2013: Bristol-Myers Squibb And AstraZeneca Announce Positive Results From Sub-Group Analysis Of Metreleptin In Pediatric Patients With Lipodystrophy

Aug 01, 2012: Shionogi Files New Drug Application For Recombinant Human Leptin For Lipodystrophy

Jun 25, 2012: New Clinical Data Analyses Show Amylin Pharma's Metreleptin Reduced Blood Glucose And Triglyceride Levels In Patients With Rare Forms Of Lipodystrophy

Apr 03, 2012: Amylin Completes Biologics License Application For Metreleptin To Treat Diabetes And/Or Hypertriglyceridemia In Patients With Rare Forms Of Lipodystrophy

Jun 04, 2011: Amylin's Study Results Show Treatment With Metreleptin Improves Diabetes And Lipid Control In Patients With Partial Lipodystrophy

Apr 15, 2011: Amylin To Present Data Showing Investigational Metreleptin Treatment Led To Long-Term Improvements In Diabetes And Lipid Control In Patients With Lipodystrophy

Dec 20, 2010: Amylin Submits Clinical And Nonclinical Sections Of Rolling Biologics License Application For Metreleptin To Treat Rare Forms Of Lipodystrophy

Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million in Qualifying Therapeutic Discovery Project Grants

Dec 16, 2008: Bolder BioTechnology Receives $1.9 million NIH Grant To Continue Development of Long-Acting Growth Hormone Product BBT-031

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Lipodystrophy, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Lipodystrophy - Pipeline by Aegerion Pharmaceuticals, Inc., H2 2016

Lipodystrophy - Pipeline by Akcea Therapeutics Inc, H2 2016

Lipodystrophy - Pipeline by Ambrx, Inc., H2 2016

Lipodystrophy - Pipeline by Amunix Operating Inc. , H2 2016

Lipodystrophy - Pipeline by Bolder Biotechnology, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016 24List of Figures

Number of Products under Development for Lipodystrophy, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Akcea Therapeutics Inc
  • Ambrx, Inc.
  • Amunix Operating Inc.
  • MORE
According to our recently published report 'Lipodystrophy – Pipeline Review, H2 2016'; Lipodystrophy pipeline therapeutics constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.

Furthermore, the publisher says; Lipodystrophy Lipodystrophy is a disorder of adipose (fatty) tissue characterized by a selective loss of body fat. Symptoms include loss of fat from beneath skin, insulin resistance, diabetes and high triglyceride level. Causes of lipodystrophy include HIV, being obese and age.

The report 'Lipodystrophy – Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Lipodystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews of key players involved in therapeutic development for Lipodystrophy and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase III and Preclinical stages are 2 and 3 respectively.
Note: Product cover images may vary from those shown
5 of 6
Aegerion Pharmaceuticals, Inc.
Akcea Therapeutics Inc
Ambrx, Inc.
Amunix Operating Inc.
Bolder Biotechnology, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll